

Supplementary File: Full list of 445 studies, bibliographic details

1. Aidong W, Zhenjie C, Tong L, et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. *Transplant Proc* 2004;36(8):2388-9 Online First.
2. Awang DVC, Kong L, Jiang W. Schisandra extract elevates concentration of tacrolimus in blood of liver transplant patients. *Focus on Alternative and Complementary Therapies* 2010;15(3):236-37 doi: 10.1111/j.2042-7166.2010.01045_9.xpublished Online First.
3. Bai DS, Dai Z, Zhou J, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. *Hepatology* 2009;49(2):460-70 doi: 10.1002/hep.22638published Online First.
4. Bu X, Zheng Z, Yu Y, et al. Significance of C4d Deposition in the Diagnosis of Rejection After Liver Transplantation. *Transplant Proc* 2006;38(5):1418-21 doi: 10.1016/j.transproceed.2006.03.018published Online First.
5. Cai CJ, Lu MQ, Chen YH, et al. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. *Clin Transplant* 2012;26(2):208-15 doi: 10.1111/j.1399-0012.2011.01448.xpublished Online First.
6. Cai Q, Li S, Jiang Y, et al. Alleviating graft injury during liver transplantation by improving retrograde perfusion in standard orthotopic liver transplantation. *Int J Clin Exp Med* 2016;9(2):4364-71 Online First.
7. Cai X, Liu F, Zhu F, et al. Cholangiographic features and endoscopic treatment of biliary strictures. *Int J Clin Exp Med* 2015;8(2):2586-92 Online First.
8. Chen B, Gu Z, Chen H, et al. Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. *Ther Drug Monit* 2010;32(5):653-60 doi: 10.1097/FTD.0b013e3181f01397published Online First.
9. Chen D, Fan J, Guo F, et al. Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients. *PLoS One* 2013;8(8) doi: 10.1371/journal.pone.0073405published Online First.

10. Chen D, Guo F, Shi J, et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients. *Drug Metab Pharmacokinet* 2014;29(3):249-53 doi: 10.2133/dmpk.DMPK-13-RG-095published Online First.
11. Chen D, Liu S, Chen S, et al. Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation. *Int J Clin Oncol* 2016;21(6):1111-19 Online First.
12. Chen G, Liu H, Hu ZQ, et al. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients. *Eur J Gastroenterol Hepatol* 2015;27(8):901-06 doi: 10.1097/MEG.0000000000000388published Online First.
13. Chen GH, Fu BS, Cai CJ, et al. A single-center experience of retransplantation for liver transplant recipients with a failing graft. *Transplant Proc* 2008;40(5):1485-87 doi: 10.1016/j.transproceed.2008.01.076published Online First.
14. Chen GH, Wang GY, Yang Y, et al. Single-center experience of therapeutic management of hepatic artery stenosis after orthotopic liver transplantation: Report of 20 cases. *Eur Surg Res* 2009;42(1):21-27 doi: 10.1159/000166601published Online First.
15. Chen GH, Yang Y, Lu MQ, et al. Liver transplantation for end-stage alcoholic liver disease: a single-center experience from mainland China. *Alcohol* 2010;44(3):217-21 doi: 10.1016/j.alcohol.2010.02.010published Online First.
16. Chen H, Chen E, Mao A, et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. *Liver Transpl* 2007;13(12):1684-93 doi: 10.1002/lt.21293published Online First.
17. Chen H, Gu Z, Chen B, et al. Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in chinese patients undergoing liver transplantation. *Clin Ther* 2008;30(12):2387-401 doi: 10.1016/j.clinthera.2008.12.017published Online First.

18. Chen H, Miao R, Fan J, et al. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. *Clin Exp Metastasis* 2013;30(5):651-58 Online First.
19. Chen H, Peng C, Yu Z, et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. *Clin Pharmacokinet* 2007;46(2):175-85 doi: 10.2165/00003088-200746020-00005published Online First.
20. Chen HY, Han ZB, Fan JW, et al. MiR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. *Med Oncol* 2012;29(3):1859-65 doi: 10.1007/s12032-011-0031-9published Online First.
21. Chen J, Li Y, Wang L, et al. Association of three SNPs in interleukin-28B with graft hepatic dysfunction after liver transplantation in Chinese Han population. *Gene* 2012;508(1):121-24 doi: 10.1016/j.gene.2012.07.065published Online First.
22. Chen J, Wang Y, Shen Z, et al. Early diagnostic value of plasma PCT and BG assay for CRBSI after OLT. *Transplant Proc* 2011;43(5):1777-79 Online First.
23. Chen J, Zhong L. Clinical significance of serum hepcidin-25 levels in predicting invasive fungal disease in patients after transplantation. *Eur Rev Med Pharmacol Sci* 2013;17(13):1769-73 Online First.
24. Chen P, Wang W, Yan L, et al. Risk factors for first-year hospital readmission after liver transplantation. *Eur J Gastroenterol Hepatol* 2015;27(5):600-06 doi: 10.1097/MEG.00000000000003272015published Online First.
25. Chen X, Meng X, Xu Y, et al. Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation. *Eur J Med Res* 2016;21(1):1-6 Online First.
26. Chen XY, Hou PF, Bi J, et al. Detection of human cytomegalovirus DNA in various blood components after liver transplantation. *Braz J Med Biol Res* 2014;47(4):340-44 Online First.
27. Chen Y, Zhang H, Xiao X, et al. Peripheral blood transcriptome sequencing reveals rejection-relevant genes in long-term heart transplantation. *Int J Cardiol* 2013;168(3):2726-33 doi: 10.1016/j.ijcard.2013.03.095published Online First.

28. Chen YB, Li SD, Ju BL, et al. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population. *Transplant Proc* 2011;43(5):1751-53 doi: 10.1016/j.transproceed.2010.11.025published Online First.
29. Chen Z, Gong R, Luo Y, et al. Surgical procedures for hepatolithiasis. *Hepatogastroenterology* 2010;57(97):134-7 Online First.
30. Chen ZS, Zeng FJ, Ming CS, et al. The survival and value of liver transplantation for liver carcinoma: a single-center experience. *Transplant Proc* 2004;36(8):2284-6 Online First.
31. Chen ZY, Yan LN, Zeng Y, et al. Preliminary Experience With Indications for Liver Transplantation for Hepatolithiasis. *Transplant Proc* 2008;40(10):3517-22 doi: 10.1016/j.transproceed.2008.07.142published Online First.
32. Cheng J, Xie HY, Xu X, et al. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. *Cancer Lett* 2011;310(1):35-45 Online First.
33. Cheng JW, Shi YH, Fan J, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2011;137(10):1445-53 doi: 10.1007/s00432-011-1014-0published Online First.
34. Cheng L, Tian F, Tang L, et al. Local distribution analysis of cytotoxic molecules in liver allograft is helpful for the diagnosis of acute cellular rejection after orthotopic liver transplantation. *Diagn Pathol* 2012;7(1) doi: 10.1186/1746-1596-7-148published Online First.
35. Cheng Y, Huang L, Zhang X, et al. Liver transplantation nearly normalizes brain spontaneous activity and cognitive function at 1 month: A resting-state functional MRI study. *Metab Brain Dis* 2015;30(4):979-88 doi: 10.1007/s11011-015-9657-1published Online First.
36. Cheng Y, Huang LX, Zhang L, et al. Longitudinal intrinsic brain activity changes in cirrhotic patients before and one month after liver transplantation. *Korean Journal of Radiology* 2017;18(2):370-77 Online First.
37. Chu Z, Zhang J, Zhao Y, et al. Influence of immunosuppressive drugs on the development of CD4 +CD25high Foxp3+ T cells in liver transplant recipients.

- Transplant Proc 2010;42(7):2599-601 doi:
10.1016/j.transproceed.2010.04.026published Online First.
38. Chuan W, Li C, Wen TF, et al. Short-term and long-term outcomes of surgical treatment for HCC within milan criteria with cirrhotic portal hypertension. *Hepatogastroenterology* 2014;61(136):2185-90 Online First.
 39. Dai X, Zhao HQ, Liu RH, et al. Percutaneous radiofrequency ablation guided by contrastenhanced ultrasound in treatment of metastatic hepatocellular carcinoma after liver transplantation. *Asian Pac J Cancer Prev* 2012;13(8):3709-12 Online First.
 40. Dai Y, Li C, Wen TF, et al. Comparison of liver resection and transplantation for Child-pugh A cirrhotic patient with very early hepatocellular carcinoma and portal hypertension. *Pakistan Journal of Medical Sciences* 2014;30(5) doi:
10.12669/pjms.305.5038published Online First.
 41. Deng JF, Geng L, Qian YG, et al. The role of toll-like receptors 2 and 4 in acute allograft rejection after liver transplantation. *Transplant Proc* 2007;39(10):3222-24 doi: 10.1016/j.transproceed.2007.02.102published Online First.
 42. Dong J, Zhu Y, Ma F, et al. Conditional disease-free survival after liver transplantation for hepatocellular carcinoma: A two-center experience. *Medicine (United States)* 2016;95(31) doi: 10.1097/MD.0000000000004383published Online First.
 43. Dong JY, Yin H, Li RD, et al. The relationship between adenosine triphosphate within CD4+ T lymphocytes and acute rejection after liver transplantation. *Clin Transplant* 2011;25(3):E292-E96 doi: 10.1111/j.1399-0012.2011.01429.xpublished Online First.
 44. Duan BW, Lu SC, Lai W, et al. The detection of (total and ccc) HBV DNA in liver transplant recipients with hepatitis B vaccine against HBV reinfection. *Human Vaccines and Immunotherapeutics* 2015;11(10):2490-94 doi:
10.1080/21645515.2015.1063755published Online First.
 45. Duan BW, Lu SC, Wu JS, et al. Model for end-stage liver disease (MELD) score does not predict outcomes of hepatitis be induced acute-on-chronic liver failure in transplant recipients. *Transplant Proc* 2014;46(10):3502-06 doi:
10.1016/j.transproceed.2014.07.075published Online First.

46. Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: A multi-center experience in Shanghai, China. *J Cancer Res Clin Oncol* 2009;135(10):1403-12 doi: 10.1007/s00432-009-0584-6published Online First.
47. Fan J, Zhang X, Chen XM, et al. Monitoring of human cytomegalovirus glycoprotein B genotypes using real-time quantitative PCR in immunocompromised Chinese patients. *J Virol Methods* 2009;160(1-2):74-77 Online First.
48. Fan J, Zhang X, Ren L, et al. Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: Results from two cohort studies. *Pharmacogenomics* 2015;16(3):239-50 doi: 10.2217/pgs.14.166published Online First.
49. Fan X, Chen Z, Nasralla D, et al. The organ preservation and enhancement of donation success ratio effect of extracorporeal membrane oxygenation in circulatory unstable brain death donor. *Clin Transplant* 2016;30(10):1306-13 Online First.
50. Fang C, Yan S, Liu J, et al. Gastrointestinal perforation after liver transplantation. *Surgical Practice* 2016;20(1):8-12 Online First.
51. Feng ZY, Xu X, Zhu SM, et al. Effects of low central venous pressure during preanhepatic phase on blood loss and liver and renal function in liver transplantation. *World J Surg* 2010;34(8):1864-73 doi: 10.1007/s00268-010-0544-ypublished Online First.
52. Fu BS, Zhang T, Li H, et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: A single-center experience. *Eur Surg Res* 2011;47(4):218-21 doi: 10.1159/000332827published Online First.
53. Fu SJ, Ji F, Han M, et al. Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation. *Oncotarget* 2017;8(3):4301-12 Online First.
54. Fu YW, Wang WG, Zhou HL, et al. Presence of donor-and-recipient-derived DNA microchimerism in the cell-free blood samples of renal transplantation recipients associates with the acceptance of transplanted kidneys. *Asian Journal of Andrology* 2006;8(4):477-82 doi: 10.1111/j.1745-7262.2006.00147.xpublished Online First.

55. Gao F, Ye Q, Wan Q, et al. Distribution and resistance of pathogens in liver transplant recipients with *Acinetobacter baumannii* infection. *Ther Clin Risk Manag* 2015;11:501-05 doi: 10.2147/TCRM.S82251published Online First.
56. Gao PJ, Gao J, Li Z, et al. Hepatocellular carcinoma recurrence is an independent risk factor for HB recurrence after liver transplantation. *Hepatogastroenterology* 2014;61(134):1523-28 doi: 10.5754/hge14454published Online First.
57. Gao PJ, Gao J, Li Z, et al. Liver transplantation in adults with portal vein thrombosis: Data from the China Liver Transplant Registry. *Clinics and Research in Hepatology and Gastroenterology* 2016;40(3):327-32 Online First.
58. Gao S, Lin BY, Yang Z, et al. Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation. *Int J Med Sci* 2014;11(3):268-75 doi: 10.7150/ijms.7769published Online First.
59. Gao S, Yang Z, Zheng ZY, et al. Reduced expression of DACT2 promotes hepatocellular carcinoma progression: Involvement of methylation-mediated gene silencing. *World J Surg Oncol* 2013;11 Online First.
60. Gao Y, Ren H, Meng F, et al. Pathological roles of interleukin-22 in the development of recurrent hepatitis C after liver transplantation. *PLoS One* 2016;11(4) doi: 10.1371/journal.pone.0154419published Online First.
61. Gao Y, Zhang M, Li J, et al. Circulating FoxP3+ regulatory T and interleukin17-producing Th17 cells actively influence HBV clearance in De Novo Hepatitis B virus infected patients after orthotopic liver transplantation. *PLoS One* 2015;10(9) doi: 10.1371/journal.pone.0137881published Online First.
62. Gao YJ, Zhang M, Jin B, et al. A clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. *Journal of Gastroenterology and Hepatology (Australia)* 2014;29(3):554-60 doi: 10.1111/jgh.12404published Online First.
63. Gu L, Jin W, Kan L, et al. A retrospective study to compare the use of tacrolimus and cyclosporine in combination with adriamycin in post-transplant liver cancer patients. *Cell Biochem Biophys* 2014;71(2):565-70 doi: 10.1007/s12013-014-0235-7published Online First.

64. Gu L, Yu YC. Clinical outcome of dental implants placed in liver transplant recipients after 3 years: A case series. *Transplant Proc* 2011;43(7):2678-82 doi: 10.1016/j.transproceed.2011.06.037published Online First.
65. Gu LH, Fang H, Li FH, et al. Prediction of early hepatic artery thrombosis by intraoperative color doppler ultrasound in pediatric segmental liver transplantation. *Clin Transplant* 2012;26(4):571-76 doi: 10.1111/j.1399-0012.2011.01580.xpublished Online First.
66. Gu Z, Chen B, Song Y, et al. Pharmacokinetics of free mycophenolic acid and limited sampling strategy for the estimation of area under the curve in liver transplant patients. *Eur J Pharm Sci* 2012;47(4):636-41 doi: 10.1016/j.ejps.2012.08.001published Online First.
67. Guo CB, Li YC, Zhang MM, et al. Early postoperative care of liver transplantation for infants with biliary atresia during pediatric intensive care unit stay. *Transplant Proc* 2010;42(5):1750-54 doi: 10.1016/j.transproceed.2010.02.086published Online First.
68. Guo QL, Duan BW, Lu SC, et al. Liver transplantation for hepatitis B-related acute-on-chronic liver failure patients. *Int J Clin Exp Med* 2017;10(2):2882-89 Online First.
69. Guo W, Sheng J, Gu Y, et al. Analysis and forecast for multidrug-resistant *Acinetobacter baumannii* infections among liver transplant recipients. *Transplant Proc* 2014;46(5):1448-52 doi: 10.1016/j.transproceed.2014.02.027published Online First.
70. Guo Z, He X, Wu L, et al. Model for end-stage liver disease versus the Child-Pugh score in predicting the post-transplant 3-month and 1-year mortality in a cohort of Chinese recipients. *Surg Today* 2010;40(1):38-45 doi: 10.1007/s00595-009-4114-6published Online First.
71. Gurbanov E, Meng X, Cui Y, et al. Evaluation ECMO in adult cardiac transplantation: can outcomes of marginal donor hearts be improved? *J Cardiovasc Surg (Torino)* 2011;52(3):419-27 Online First.
72. Han ZB, Chen HY, Fan JW, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. *J Cancer Res Clin Oncol* 2011:1-9 Online First.

73. Han ZB, Zhong L, Teng MJ, et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. *Mol Oncol* 2012;6(4):445-57 doi: 10.1016/j.molonc.2012.04.001published Online First.
74. Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. *Liver Transpl* 2008;14(8):1165-73 Online First.
75. Hao C, Erzheng C, Anwei M, et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. *Liver Transpl* 2007;13(12):1684-93 Online First.
76. Hei Z, Chi X, Cheng N, et al. Upregulation of TLR2/4 expression in mononuclear cells in postoperative systemic inflammatory response syndrome after liver transplantation. *Mediators Inflamm* 2010;2010 doi: 10.1155/2010/519589published Online First.
77. Hu B, Gao DJ, Yu FH, et al. Endoscopic stenting for post-transplant biliary stricture: Usefulness of a novel removable covered metal stent. *Journal of Hepato-Biliary-Pancreatic Sciences* 2011;18(5):640-45 doi: 10.1007/s00534-011-0408-3published Online First.
78. Hu J, Wang Z, Fan J, et al. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. *PLoS One* 2011;6(10) doi: 10.1371/journal.pone.0026003published Online First.
79. Hu J, Xie X, Li Y, et al. A novel noninvasive method to detect rejection after heart transplantation. *Braz J Med Biol Res* 2012;45(12):1195-201 doi: 10.1590/S0100-879X2012007500164published Online First.
80. Hu WY, Wu LQ, Su Z, et al. Expression of human leukocyte antigen-G and acute rejection in patients following liver transplantation. *Exp Ther Med* 2014;8(4):1291-95 doi: 10.3892/etm.2014.1917published Online First.
81. Hu XX, Yan LN. Retrospective analysis of prognostic factors after liver transplantation for intrahepatic cholangiocarcinoma in China: A single-center experience. *Hepatogastroenterology* 2011;58(109):1255-59 doi: 10.5754/hge10704published Online First.

82. Hu Y, Zhang X, Liu Y, et al. APACHE IV is superior to MELD scoring system in predicting prognosis in patients after orthotopic liver transplantation. *Clinical and Developmental Immunology* 2013;2013 doi: 10.1155/2013/809847published Online First.
83. Hu Z, Zhou J, Li Z, et al. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: Retrospective study of the Milan and Hangzhou criteria. *PLoS One* 2014;9(1) doi: 10.1371/journal.pone.0087222published Online First.
84. Hu Z, Zhou J, Li Z, et al. Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus. *Surgery (United States)* 2015;157(2):239-48 doi: 10.1016/j.surg.2014.09.018published Online First.
85. Huang J, Yan L, Wu H, et al. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? *J Surg Res* 2016;200(1):122-30 Online First.
86. Huang L, Li GM, Zhu JY, et al. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: A preliminary study. *Onco Targets Ther* 2012;5:457-62 doi: 10.2147/OTT.S31387published Online First.
87. Huang M, Shan H, Jiang Z, et al. The use of coronary stent in hepatic artery stenosis after orthotopic liver transplantation. *Eur J Radiol* 2006;60(3):425-30 doi: 10.1016/j.ejrad.2006.06.008published Online First.
88. Huang Q, Zhai RY, Dai DK. Interventional Treatment of Hepatic Artery Stenosis After Orthotopic Liver Transplantation With Balloon-Expandable Coronary Stent. *Transplant Proc* 2007;39(10):3245-50 doi: 10.1016/j.transproceed.2007.03.109published Online First.
89. Huang Y, Yang X, Zhao F, et al. Overexpression of Dickkopf-1 predicts poor prognosis for patients with hepatocellular carcinoma after orthotopic liver transplantation by promoting cancer metastasis and recurrence. *Med Oncol* 2014;31(7) Online First.

90. Huang ZY, Liang BY, Xiong M, et al. Severity of cirrhosis should determine the operative modality for patients with early hepatocellular carcinoma and compensated liver function. *Surgery (United States)* 2016;159(2):621-31 Online First.
91. Huijun M, Ji Z, Ping X, et al. Linkage disequilibrium between *tnf- α* -308 G/A promoter and histocompatibility leukocyte antigen alleles in han-nationality lung transplant recipients from eastern china. *Exp Clin Transplant* 2013;11(3):264-69 doi: 10.6002/ect.2012.0099published Online First.
92. Jiang GQ, Bai DS, Chen P, et al. Starting hemoglobin value predicts early phase prognosis after liver transplantation. *Transplant Proc* 2011;43(5):1669-73 doi: 10.1016/j.transproceed.2010.12.067published Online First.
93. Jiang L, Lei JY, Wang WT, et al. Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE. *J Gastrointest Surg* 2014;18(6):1125-30 Online First.
94. Jiang T, Li C, Duan B, et al. Risk factors for and management of ischemic-type biliary lesions following orthotopic liver transplantation: A single center experience. *Ann Hepatol* 2016;15(1):41-46 doi: 10.5604/16652681.1184204published Online First.
95. Jiang T, Liu S, Xiao X, et al. Diagnosis of rejection after liver transplantation: Use of phosphorus-31 magnetic resonance spectroscopy (31P-MRS). *Abdom Imaging* 2012;37(5):788-94 doi: 10.1007/s00261-008-9451-1published Online First.
96. Jiang Z, Chen Y, Feng X, et al. Recipient cytotoxic T lymphocyte antigen 4 +49 single-nucleotide polymorphism is not associated with acute rejection after liver transplantation in Chinese population. *Int J Med Sci* 2013;10(3):250-54 doi: 10.7150/ijms.5511published Online First.
97. Jiang Z, Feng X, Zhang W, et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients. *Liver International* 2007;27(9):1202-08 doi: 10.1111/j.1478-3231.2007.01553.xpublished Online First.
98. Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis b in Chinese patients after liver transplantation using lamivudine combined with Hepatitis B immune globulin

- according to the titer of antibody to Hepatitis B surface antigen. *Transplant Proc* 2007;39(5):1533-36 doi: 10.1016/j.transproceed.2007.03.062published Online First.
99. Jin R, Duan H, Zhao C, et al. Pharmacokinetics of cyclosporine A in Chinese heart transplant recipients. *Immunopharmacol Immunotoxicol* 2012;34(3):519-22 doi: 10.3109/08923973.2011.613400published Online First.
 100. Jin Z, Zhang WX, Chen B, et al. Stepwise regression analysis of the determinants of blood tacrolimus concentrations in Chinese patients with liver transplant. *Medicinal Chemistry* 2009;5(3):301-04 doi: 10.2174/157340609788185918published Online First.
 101. Ju W, Chen M, Guo Z, et al. Allografts positive for hepatitis B surface antigen in liver transplant for disease related to hepatitis B virus. *Exp Clin Transplant* 2013;11(3):245-49 doi: 10.6002/ect.2012.0095published Online First.
 102. Ju WQ, Guo ZY, Liang WH, et al. Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: Efficacy and safety. *Exp Clin Transplant* 2012;10(2):132-35 doi: 10.6002/ect.2010.0126published Online First.
 103. Ju WQ, Guo ZY, Ling X, et al. Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients. *Exp Clin Transplant* 2012;10(3):258-62 doi: 10.6002/ect.2010.0127published Online First.
 104. Kong HY, Huang SQ, Zhu SM, et al. Role of anhepatic time in endothelial-related coagulation in liver transplantation. *Minerva Anesthesiol* 2013;79(4):391-97 Online First.
 105. Kong HY, Wen XH, Huang SQ, et al. Epsilon-aminocaproic acid improves postrecirculation hemodynamics by reducing intraliver activated protein C consumption in orthotopic liver transplantation. *World J Surg* 2014;38(1):177-85 doi: 10.1007/s00268-013-2282-4published Online First.
 106. Lai MC, Yang Z, Zhou L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. *Med Oncol* 2012;29(3):1810-16 doi: 10.1007/s12032-011-0004-zpublished Online First.
 107. Lei J, Wang W, Yan L. Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. *J Gastrointest Surg* 2013;17(8):1440-6 Online First.

108. Lei J, Yan L. Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies. *J Gastrointest Surg* 2013;17(6):1116-22 doi: 10.1007/s11605-013-2140-6published Online First.
109. Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: A single-center experience. *Eur J Gastroenterol Hepatol* 2014;26(2):200-04 doi: 10.1097/MEG.0b013e3283652b66published Online First.
110. Lei JY, Yan LN, Wang WT, et al. Health-related quality of life and psychological distress in patients with early-stage hepatocellular carcinoma after hepatic resection or transplantation. *Transplant Proc* 2016;48(6):2107-11 Online First.
111. Lei JY, Yan LN, Zhu JQ, et al. Hepatocellular carcinoma patients may benefit from postoperative huaier aqueous extract after liver transplantation. *Transplant Proc* 2015;47(10):2920-24 doi: 10.1016/j.transproceed.2015.10.045published Online First.
112. Li C, Zhang F, Zhang W, et al. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2010;136(11):1633-40 doi: 10.1007/s00432-010-0821-zpublished Online First.
113. Li C, Zhu WJ, Wen TF, et al. Child-Pugh A Hepatitis B-Related Cirrhotic Patients with a Single Hepatocellular Carcinoma Up to 5 cm: Liver Transplantation vs. Resection. *J Gastrointest Surg* 2014;18(8):1469-76 doi: 10.1007/s11605-014-2550-0published Online First.
114. Li D, Lu T, Shen C, et al. Expression of fibroblast growth factor 21 in patients with biliary atresia. *Cytokine* 2016;83:13-18 Online First.
115. Li D, Lu W, Zhu JY, et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. *J Clin Pharm Ther* 2007;32(5):505-15 doi: 10.1111/j.1365-2710.2007.00850.xpublished Online First.
116. Li D, Zhu JY, Gao J, et al. Polymorphisms of tumor necrosis factor- α , interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. *Clin Chim Acta* 2007;383(1-2):133-39 doi: 10.1016/j.cca.2007.05.008published Online First.

117. Li F, Yang M, Li B, et al. Initial clinical results of orthotopic liver transplantation for hepatic alveolar echinococcosis. *Liver Transpl* 2007;13(6):924-26 doi: 10.1002/lt.21187published Online First.
118. Li H, He JW, Fu BS, et al. Immunosuppressant-related hip pain after orthotopic liver transplant. *Exp Clin Transplant* 2013;11(1):32-38 doi: 10.6002/ect.2012.0026published Online First.
119. Li H, Li B, Wei Y, et al. Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience. *Clinics and Research in Hepatology and Gastroenterology* 2015;39(4):451-57 doi: 10.1016/j.clinre.2014.12.004published Online First.
120. Li H, Li J, Wang Y, et al. Proteomic analysis of effluents from perfused human heart for transplantation: Identification of potential biomarkers for ischemic heart damage. *Proteome Science* 2012;10(1) doi: 10.1186/1477-5956-10-21published Online First.
121. Li H, Wang S, Wang G, et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. *Dig Surg* 2014;31(6):468-78 doi: 10.1159/000370252published Online First.
122. Li H, Xie HY, Zhou L, et al. Copy number variation in CCL3L1 gene is associated with susceptibility to acute rejection in patients after liver transplantation. *Clin Transplant* 2012;26(2):314-21 doi: 10.1111/j.1399-0012.2011.01486.xpublished Online First.
123. Li H, Xie HY, Zhou L, et al. Lack of association of the polymorphism of the CCR5 gene in liver recipients with acute rejection from China. *Exp Clin Transplant* 2011;9(4):252-57 Online First.
124. Li H, Yang S, Chen H, et al. Survival after heart transplantation for non-metastatic primary cardiac sarcoma. *J Cardiothorac Surg* 2016;11(1):145 Online First.
125. Li J, Bai Y, Wang L, et al. Regulatory Effect of FK506 on CD152 and PD-1 in the Liver Allorecipients. *Transplant Proc* 2008;40(5):1495-97 Online First.
126. Li J, Liu B, Yan LN, et al. Reversal of graft steatosis after liver transplantation: prospective study. *Transplant Proc* 2009;41(9):3560-63 doi: 10.1016/j.transproceed.2009.06.222published Online First.

127. Li MR, Chen GH, Cai CJ, et al. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. *Digestion* 2011;84(2):134-41 doi: 10.1159/000324197published Online First.
128. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. *Clin Cancer Res* 2007;13(19):5847-54 Online First.
129. Li Q, Yao G, Ge Q, et al. Relevant risk factors affecting time of ventilation during early postoperative period after orthotopic liver transplantation. *J Crit Care* 2010;25(2):221-24 doi: 10.1016/j.jcrc.2009.06.048published Online First.
130. Li QY, Qin YS, Ling Q, et al. No therapeutic ERCP in anastomotic stricture without intrahepatic biliary dilation after liver transplantation. *Hepatogastroenterology* 2011;58(109):1127-31 doi: 10.5754/hge11268published Online First.
131. Li RD, Sun Z, Dong JY, et al. A quantitative assessment model of T-cell immune function for predicting risks of infection and rejection during the early stage after liver transplantation. *Clin Transplant* 2013;27(5):666-72 doi: 10.1111/ctr.12187published Online First.
132. Li T, Chen ZS, Zeng FJ, et al. Impact of early biliary complications in liver transplantation in the presence or absence of a T-tube: A Chinese transplant centre experience. *Postgrad Med J* 2007;83(976):120-23 doi: 10.1136/pgmj.2006.049171published Online First.
133. Li W, Yuan G, Liu H, et al. Comparison of HPLC-MS/MS and enzyme-multiplied immunoassay in tacrolimus determination and its application in therapeutic drug monitoring. *Latin American Journal of Pharmacy* 2015;34(8):1540-46 Online First.
134. Li WX, Li Z, Gao PJ, et al. Histological differentiation predicts post-liver transplantation survival time. *Clinics and Research in Hepatology and Gastroenterology* 2014;38(2):201-08 doi: 10.1016/j.clinre.2013.11.002published Online First.
135. Li X, Chi X, Luo G, et al. Ulinastatin ameliorates acute kidney injury following liver transplantation in rats and humans. *Exp Ther Med* 2015;9(2):411-16 Online First.

136. Li X, Li X, Chi X, et al. Ulinastatin ameliorates acute kidney injury following liver transplantation in rats and humans. *Exp Ther Med* 2015;9(2):411-16 doi: 10.3892/etm.2014.2088published Online First.
137. Li Y, Shi Y, Chen J, et al. Association of polymorphisms in interleukin-18 and interleukin-28b with hepatitis b recurrence after liver transplantation in chinese han population. *Int J Immunogenet* 2012;39(4):346-52 doi: 10.1111/j.1744-313X.2012.01097.xpublished Online First.
138. Li Y, Zhu M, Xia Q, et al. Urinary neutrophil gelatinase-associated lipocalin and L-type fatty acid binding protein as diagnostic markers of early acute kidney injury after liver transplantation. *Biomarkers* 2012;17(4):336-42 doi: 10.3109/1354750X.2012.672458published Online First.
139. Li Y, Zou Y, Cai B, et al. The associations of IL-18 serum levels and promoter polymorphism with tacrolimus pharmacokinetics and hepatic allograft dysfunction in Chinese liver transplantation recipients. *Gene* 2012;491(2):251-55 doi: 10.1016/j.gene.2011.10.008published Online First.
140. Liang TB, Bai XL, Li DL, et al. Early Postoperative hemorrhage requiring urgent surgical reintervention after orthotopic liver transplantation. *Transplant Proc* 2007;39(5):1549-53 doi: 10.1016/j.transproceed.2007.01.080published Online First.
141. Liang TB, Li DL, Liang L, et al. Intraoperative blood salvage during liver transplantation in patients with hepatocellular carcinoma: Efficiency of leukocyte depletion filters in the removal of tumor cells. *Transplantation* 2008;85(6):863-69 doi: 10.1097/TP.0b013e3181671f2epublished Online First.
142. Liang TB, Li JJ, Li DL, et al. Intraoperative blood salvage and leukocyte depletion during liver transplantation with bacterial contamination. *Clin Transplant* 2010;24(2):265-72 doi: 10.1111/j.1399-0012.2009.01091.xpublished Online First.
143. Lianghui G, Shusen Z, Tingbo L, et al. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation. *Transplant Proc* 2004;36(5):1502-05 doi: 10.1016/j.transproceed.2004.04.079published Online First.
144. Lin B, Geng L, Zheng Z, et al. The predictive value of blood neutrophil-lymphocyte ratio in patients with end-stage liver cirrhosis following ABO-incompatible liver transplantation. *J Res Med Sci* 2016;21(5):20-25 Online First.

145. Lin MJ, Yang YL, Yu Q, et al. Value of percutaneous transhepatic cholangioscopy in the treatment of biliary cast after liver transplantation. *Int J Clin Exp Med* 2016;9(2):1263-71 Online First.
146. Lin XH, Teng S, Wang L, et al. Fatigue and its associated factors in liver transplant recipients in Beijing: A cross-sectional study. *BMJ Open* 2017;7 (2) Online First.
147. Lin YH, Cai ZS, Jiang Y, et al. Perioperative risk factors for pulmonary complications after liver transplantation. *J Int Med Res* 2010;38(5):1845-55 Online First.
148. Ling L, He X, Zeng J, et al. In-hospital cerebrovascular complications following orthotopic liver transplantation: a retrospective study. *BMC Neurol* 2008;8:52 Online First.
149. Ling Q, Xie H, Li J, et al. Donor Graft MicroRNAs: A Newly Identified Player in the Development of New-onset Diabetes After Liver Transplantation. *Am J Transplant* 2017;17(1):255-64 Online First.
150. Ling Q, Xie H, Lu D, et al. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. *J Hepatol* 2013;58(2):271-77 doi: 10.1016/j.jhep.2012.09.025published Online First.
151. Ling Q, Xu X, Li J, et al. A new serum cystatin C-based equation for assessing glomerular filtration rate in liver transplantation. *Clin Chem Lab Med* 2008;46(3):405-10 doi: 10.1515/CCLM.2008.052published Online First.
152. Ling Q, Xu X, Wang K, et al. Donor PPAR γ Gene polymorphisms influence the susceptibility to glucose and lipid disorders in liver transplant recipients. *medicine (United States)* 2015;94(35):e1421 doi: 10.1097/MD.0000000000001421published Online First.
153. Ling Q, Xu X, Wei Q, et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. *PLoS One* 2012;7(1) doi: 10.1371/journal.pone.0030322published Online First.
154. Ling Q, Xu X, Wei Q, et al. Impact of preexisting diabetes mellitus on outcome after liver transplantation in patients with hepatitis B virus-related liver disease. *Dig Dis Sci* 2011;56(3):889-93 doi: 10.1007/s10620-010-1358-3published Online First.

155. Liu B, Teng F, Fu H, et al. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. *BMC Gastroenterol* 2015;15(1) doi: 10.1186/s12876-015-0364-5published Online First.
156. Liu C, Shang YF, Zhang XF, et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: A prospective study. *Eur J Clin Pharmacol* 2009;65(9):881-85 doi: 10.1007/s00228-009-0702-zpublished Online First.
157. Liu C, Tsai HL, Chin T, et al. Experience of surgical treatment for hepatoblastoma. *Formosan Journal of Surgery* 2016;49(2):56-62 Online First.
158. Liu CZ, Hu SY, Jin B, et al. Hemodialysis-induced hyperglycemia after liver transplantation. *Hepatogastroenterology* 2008;55(88):2175-77 Online First.
159. Liu D, Huang P, Li X, et al. Using inflammatory and oxidative biomarkers in urine to predict early acute kidney injury in patients undergoing liver transplantation. *Biomarkers* 2014;19(5):424-29 doi: 10.3109/1354750X.2014.924997published Online First.
160. Liu D, Luo G, Luo C, et al. Changes in the concentrations of mediators of inflammation and oxidative stress in exhaled breath condensate during liver transplantation and their relations with postoperative ARDS. *Respir Care* 2015;60(5):679-88 doi: 10.4187/respcare.03311published Online First.
161. Liu J, Yan J, Wan Q, et al. The risk factors for tuberculosis in liver or kidney transplant recipients. *BMC Infect Dis* 2014;14(1) doi: 10.1186/1471-2334-14-387published Online First.
162. Liu S, Bai Y, Huang J, et al. Do mitochondria contribute to left ventricular non-compaction cardiomyopathy? New findings from myocardium of patients with left ventricular non-compaction cardiomyopathy. *Mol Genet Metab* 2013;109(1):100-06 Online First.
163. Liu S, Fan J, Wang X, et al. Intraoperative cryoprecipitate transfusion and its association with the incidence of biliary complications after liver transplantation-a retrospective cohort study. *PLoS One* 2013;8(5) doi: 10.1371/journal.pone.0060727published Online First.

164. Liu S, Wang X, Lu Y, et al. The effects of intraoperative cryoprecipitate transfusion on acute renal failure following orthotopic liver transplantation. *Hepatology International* 2013;7(3):901-09 doi: 10.1007/s12072-013-9457-9 published Online First.
165. Liu S, Xing T, Sheng T, et al. The reduction rate of serum C3 following liver transplantation is an effective predictor of non-anastomotic strictures. *Hepatology International* 2014;8(2):293-300 doi: 10.1007/s12072-014-9524-x published Online First.
166. Liu X, Wang B, Zhang X, et al. Liver transplantation using donation after brain and cardiac death: a single-center experience in China. *Transplant Proc* 2016;48(6):1879-86 Online First.
167. Liu XX, Xu BM, Chen H, et al. limited sampling strategy for the estimation of tacrolimus area under the concentration-time curve in Chinese adult liver transplant patients. *Pharmacology* 2016;98(5-6):229-41 doi: 10.1159/000445896 published Online First.
168. Liu Y, Liu YY, Li CP, et al. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: Steroid-free immunosuppression, induction immunosuppression and standard immunosuppression. *PLoS One* 2015;10 (3) Online First.
169. Liu Y, Sun LY, Zhu ZJ, et al. Measles virus infection in pediatric liver transplantation recipients. *Transplant Proc* 2015;47(9):2715-8 Online First.
170. Liu Z, Yu X, Ren W, et al. CD152 and PD-1 down-regulation on CD8 T cells is associated with human acute liver allograft rejection. *Transplant Proc* 2014;46(10):3511-4 Online First.
171. Liu ZN, Wang WT, Yan LN. De Novo malignancies after liver transplantation with 14 cases at a single center. *Transplant Proc* 2015;47(8):2483-87 doi: 10.1016/j.transproceed.2015.08.008 published Online First.
172. Lu D, Xu X, Wang J, et al. The influence of a contemporaneous portal and hepatic artery revascularization protocol on biliary complications after liver transplantation. *Surgery (United States)* 2014;155(1):190-95 doi: 10.1016/j.surg.2013.06.056 published Online First.

173. Lu H, He J, Wu Z, et al. Assessment of microbiome variation during the perioperative period in liver transplant patients: a retrospective analysis. *Microb Ecol* 2013;65(3):781-91 doi: 10.1007/s00248-013-0211-6published Online First.
174. Lu HW, Dong JH, Li CH, et al. The defects of cholangiocyte primary cilia in patients with graft cholangiopathies. *Clin Transplant* 2014;28(10):1202-08 Online First.
175. Lu NN, Huang Q, Wang JF, et al. Non-anastomotic biliary strictures following orthotopic liver transplantation: Treatment with percutaneous transhepatic biliary drainage. *Hepatogastroenterology* 2012;59(120):2569-72 doi: 10.5754/hge12300published Online First.
176. Lu Q, Zhong XF, Huang ZX, et al. Role of contrast-enhanced ultrasound in decision support for diagnosis and treatment of hepatic artery thrombosis after liver transplantation. *Eur J Radiol* 2012;81(3):e338-e43 doi: 10.1016/j.ejrad.2011.11.015published Online First.
177. Lu SC, Jiang T, Lai W, et al. Reestablishment of active immunity against HBV graft reinfection after liver transplantation for HBV-related end stage liver disease. *Journal of immunology research* 2014;2014:764234 Online First.
178. Luo A, Wan Q, Ye Q, et al. The clinical manifestations and distribution and resistance of pathogens among liver transplantation with infections caused by non - Fermenters: A clinical analysis of 31 patients. *Hepatogastroenterology* 2014;61(136):2349-52 doi: 10.5754/hge14849published Online First.
179. Luo A, Zhong Z, Wan Q, et al. The distribution and resistance of pathogens among solid organ transplant recipients with *Pseudomonas aeruginosa* infections. *Med Sci Monit* 2016;22:1124-30 doi: 10.12659/MSM.896026published Online First.
180. Luo XJ, Wang W, Hu SS, et al. Extracorporeal membrane oxygenation for treatment of cardiac failure in adult patients. *Interact Cardiovasc Thorac Surg* 2009;9(2):296-300 Online First.
181. Luo YL, Yang XL, Cui JB, et al. Health-related quality of life of liver transplant recipients: A single center experience. *Hepatogastroenterology* 2012;59(118):1947-50 doi: 10.5754/hge12008published Online First.
182. Lv Z, Cai X, Weng X, et al. Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. *Surgery*

- (United States) 2015;158(1):142-50 doi: 10.1016/j.surg.2015.02.013published Online First.
183. Lv Z, Weng X, Du C, et al. Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients. *Mol Carcinog* 2016;55(5):1024-33 doi: 10.1002/mc.22345published Online First.
 184. Lyu SQ, Ren J, Zheng RQ, et al. Contrast-enhanced sonography for diagnosing collateral transformation of the hepatic artery after liver transplantation. *J Ultrasound Med* 2015;34(9):1591-98 doi: 10.7863/ultra.15.14.08079published Online First.
 185. Mao W, Chen J, Zheng M, et al. Initial experience of lung transplantation at a single center in China. *Transplant Proc* 2013;45(1):349-55 doi: 10.1016/j.transproceed.2012.02.045published Online First.
 186. Mao W, Hu Y, Lou Y, et al. Immature platelet fraction values predict recovery of platelet counts following liver transplantation. *Clinics and Research in Hepatology and Gastroenterology* 2015;39(4):469-74 doi: 10.1016/j.clinre.2014.11.008published Online First.
 187. Mao WJ, Chen JY, Zheng MF, et al. Lung transplantation for end-stage silicosis. *J Occup Environ Med* 2011;53(8):845-49 doi: 10.1097/JOM.0b013e3182260e50published Online First.
 188. Men TY, Wang JN, Li H, et al. Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum β -lactamases (ESBLs) and ESBL genes in solid organ transplant recipients. *Transpl Infect Dis* 2013;15(1):14-21 doi: 10.1111/tid.12001published Online First.
 189. Meng X, Chen X, Wu L, et al. The hyperlipidemia caused by overuse of glucocorticoid after liver transplantation and the immune adjustment strategy. *Journal of Immunology Research* 2017;2017 Online First.
 190. Minmin S, Zhidong G, Hao C, et al. Correlation between pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients. *J Clin Pharmacol* 2010;50(12):1388-96 doi: 10.1177/0091270009359526published Online First.

191. Mu HJ, Xie P, Chen JY, et al. Association of TNF- α , TGF- β 1, IL-10, IL-6, and IFN- γ gene polymorphism with acute rejection and infection in lung transplant recipients. *Clin Transplant* 2014;28(9):1016-24 doi: 10.1111/ctr.12411 published Online First.
192. Niu Y, Chen X, Feng L, et al. Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. *Clinics and Research in Hepatology and Gastroenterology* 2014;38(4):475-80 Online First.
193. Niu YJ, Shen ZY, Xu C, et al. Establishment of tacrolimus-induced diabetes in rat model and assessment of clinical treatments for post-transplant diabetes mellitus in liver transplant recipients. *Clinical Laboratory* 2013;59(7-8):869-74 doi: 10.7754/Clin.Lab.2012.120913 published Online First.
194. Pan C, Shi Y, Zhang JJ, et al. Single-center experience of 253 portal vein thrombosis patients undergoing liver transplantation in China. *Transplant Proc* 2009;41(9):3761-65 doi: 10.1016/j.transproceed.2009.06.215 published Online First.
195. Pan C, Wang C, Pan W, et al. Usefulness of real-time three-dimensional echocardiography to quantify global left ventricular function and mechanical dyssynchrony after heart transplantation. *Acta Cardiol* 2011;66(3):365-70 doi: 10.2143/AC.66.3.2114137 published Online First.
196. Pan L, Zhang W, Zhang J, et al. The analysis of CD45 isoforms expression on HBV-specific T cells after liver transplantation. *Med Oncol* 2012;29(2):899-908 doi: 10.1007/s12032-011-9833-z published Online First.
197. Pei F, Shang K, Jiang B, et al. Clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B viral infection. *Hepatology International* 2013;7(2):468-76 doi: 10.1007/s12072-013-9422-7 published Online First.
198. Peng C, Zhang Z, Wu J, et al. A critical role for ZDHHC2 in metastasis and recurrence in human hepatocellular carcinoma. *BioMed Research International* 2014;2014 Online First.
199. Qiao B, Wu J, Wan Q, et al. Factors influencing mortality in abdominal solid organ transplant recipients with multidrug-resistant gram-negative bacteremia. *BMC Infect Dis* 2017;17 (1) Online First.

200. Qin J, Fang Y, Dong Y, et al. Radiological and clinical findings of 25 patients with invasive pulmonary aspergillosis: Retrospective analysis of 2150 liver transplantation cases. *Br J Radiol* 2012;85(1016):e429-e35 doi: 10.1259/bjr/39784231published Online First.
201. Qin J, Xu J, Dong Y, et al. High-resolution CT findings of pulmonary infections after orthotopic liver transplantation in 453 patients. *Br J Radiol* 2012;85(1019):e959-e65 doi: 10.1259/bjr/26230943published Online First.
202. Qin Z, Linghu EQ. New endoscopic classification system for biliary stricture after liver transplantation. *J Int Med Res* 2014;42(2):566-71 doi: 10.1177/0300060513507761published Online First.
203. Qiu Y, Zhu X, Wang W, et al. Nutrition support with glutamine dipeptide in patients undergoing liver transplantation. *Transplant Proc* 2009;41(10):4232-37 doi: 10.1016/j.transproceed.2009.08.076published Online First.
204. Qu W, Zhu ZJ, Sun LY, et al. Correlation between immunosuppressive therapy and CD4⁺ T-Cell intracellular adenosine triphosphate levels in liver transplant recipients. *Transplant Proc* 2016;48(6):2094-97 Online First.
205. Qu W, Zhu ZJ, Sun LY, et al. Correlation between survival interval and CD4⁺ T-Cell intracellular ATP levels in liver transplant recipients. *Transplant Proc* 2017;49(2):316-21 Online First.
206. Qu W, Zhu ZJ, Sun LY, et al. Salvage liver transplantation for hepatocellular carcinoma recurrence after primary liver resection. *Clinics and Research in Hepatology and Gastroenterology* 2015;39(1):93-97 doi: 10.1016/j.clinre.2014.07.006published Online First.
207. Ran JH, Zhang SN, Liu J, et al. In-hospital and follow-up outcomes of patients undergoing orthotopic liver transplantation after hepatic artery reconstruction with an iliac interposition graft. *Int J Clin Exp Med* 2016;9(2):3939-45 Online First.
208. Ren J, Lu MD, Zheng RQ, et al. Evaluation of the microcirculatory disturbance of biliary ischemia after liver transplantation with contrast-enhanced ultrasound: Preliminary experience. *Liver Transpl* 2009;15(12):1703-08 doi: 10.1002/lt.21910published Online First.

209. Ren J, Zheng BW, Wang P, et al. Revealing impaired blood supply to the bile ducts on contrast-enhanced ultrasound: a novel diagnosis method to ischemic-type biliary lesions after orthotopic liver transplantation. *Ultrasound Med Biol* 2013;39(5):753-60 doi: 10.1016/j.ultrasmedbio.2012.12.004published Online First.
210. Ren L, Teng M, Zhang T, et al. Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients. *Pharmacogenomics* 2017;18(3):265-75 Online First.
211. Ren QQ, Fu SJ, Zhao Q, et al. Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation. *Tumor Biology* 2016;37(7):8973-78 Online First.
212. Ren X, Guan J, Gao N, et al. Evaluation of pediatric liver transplantation-related artery complications using intra-operative multi-parameter ultrasonography. *Med Sci Monit* 2016;22:4495-502 Online First.
213. Ren X, Luo Y, Gao N, et al. Common ultrasound and contrast-enhanced ultrasonography in the diagnosis of hepatic artery pseudoaneurysm after liver transplantation. *Exp Ther Med* 2016;12(2):1029-33 Online First.
214. Sha J, Tao Y, Li D, et al. Outcome of heart transplantations done in our centre. *Ann Transplant* 2008;13(3):27-29 Online First.
215. Shan Y, Shen N, Han L, et al. MicroRNA-499 Rs3746444 polymorphism and biliary atresia. *Dig Liver Dis* 2016;48(4):423-28 Online First.
216. Shaoyin D, Yongmei Y, Tong S, et al. Follow-up examination of 12 heart transplant recipients with cardiac CT. *Clin Imaging* 2012;36(6):732-38 doi: 10.1016/j.clinimag.2012.02.004published Online First.
217. Shen C, Peng C, Shen B, et al. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation. *Oncotarget* 2016;7(38):62647-56 Online First.
218. Shen JY, Li C, Wen TF, et al. Liver transplantation versus surgical resection for CC meeting the Milan criteria: A propensity score analysis. *Medicine (United States)* 2016;95(52) doi: 10.1097/MD.0000000000005756published Online First.

219. Shen Z, Zhu Z, Zhang Y, et al. Liver transplantation at Tianjin First Central Hospital. *Clin Transpl* 2005;221-23 Online First.
220. Shen ZY, Zheng WP, Deng YL, et al. Variations in the S and P regions of the hepatitis B virus genome under immunosuppression in vitro and in vivo. *Viral Immunol* 2012;25(5):368-78 Online First.
221. Sheng H, Lu Y, Chen H. Ocular complications of heart transplantation in a Chinese population. *Transplant Proc* 2008;40(10):3590-93 doi: 10.1016/j.transproceed.2008.06.081published Online First.
222. Sheng L, Jun S, Jianfeng L, et al. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation. *Clin Transplant* 2015;29(6):555-59 doi: 10.1111/ctr.12552published Online First.
223. Shi F, Zhang JY, Zeng Z, et al. Skewed ratios between CD3⁺ T cells and monocytes are associated with poor prognosis in patients with HBV-related acute-on-chronic liver failure. *Biochem Biophys Res Commun* 2010;402(1):30-36 Online First.
224. Shi R, Shen ZY, Teng da H, et al. Gallstones in liver transplant recipients: A single-center study in China. *Turkish Journal of Gastroenterology* 2015;26(5):429-34 Online First.
225. Shi SH, Kong HS, Jia CK, et al. Risk factors for pneumonia caused by multidrug-resistant Gram-negative bacilli among liver recipients. *Clin Transplant* 2010;24(6):758-65 Online First.
226. Shi SH, Kong HS, Xu J, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. *Transpl Infect Dis* 2009;11(5):405-12 doi: 10.1111/j.1399-3062.2009.00421.xpublished Online First.
227. Shi Y, Li Y, Tang J, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. *Gene* 2013;512(2):226-31 doi: 10.1016/j.gene.2012.10.048published Online First.

228. Shi Z, Yan L, Zhao J, et al. Prevention and treatment of rethrombosis after liver transplantation with an implantable pump of the portal vein. *Liver Transpl* 2010;16(3):324-31 doi: 10.1002/lt.21988published Online First.
229. Song SH, Li XX, Wan QQ, et al. Risk factors for mortality in liver transplant recipients with ESKAPE infection. *Transplant Proc* 2014;46(10):3560-63 doi: 10.1016/j.transproceed.2014.08.049published Online First.
230. Su H, Liu Z, Sun Y, et al. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation. *Ann Transplant* 2015;20:263-68 doi: 10.12659/AOT.892255published Online First.
231. Su H, Ye Q, Wan Q, et al. Predictors of mortality in abdominal organ transplant recipients with pseudomonas aeruginosa infections. *Ann Transplant* 2016;21 Online First.
232. Sun B, Li XY, Gao JW, et al. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. *Ther Drug Monit* 2010;32(6):715-22 doi: 10.1097/FTD.0b013e3181fb6ce3published Online First.
233. Sun H, Teng M, Liu J, et al. FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. *Cancer Lett* 2011;306(2):214-22 doi: 10.1016/j.canlet.2011.03.009published Online First.
234. Sun J, Cao G, Zhang L, et al. Human cytomegalovirus (CMV) UL97 D605E mutation has a higher prevalence in infants with primary CMV infection compared with transplant recipients with CMV recurrence. *Transplant Proc* 2012;44(10):3022-25 doi: 10.1016/j.transproceed.2012.06.069published Online First.
235. Sun XY, Dong JH, Qin K, et al. Single center study on transplantation of livers donated after cardiac death: A report of 6 cases. *Exp Ther Med* 2016;11(3):988-92 doi: 10.3892/etm.2016.3001published Online First.
236. Sun Y, Yin S, Xie H, et al. Immunophenotypic shift of memory CD8 T cells identifies the changes of immune status in the patients after liver transplantation. *Scand J Clin Lab Invest* 2009;69(7):789-96 doi: 10.3109/00365510903268818published Online First.

237. Teng da H, Zhu ZJ, Zheng H, et al. Effect of steatosis donor liver transplantation on hepatocellular carcinoma recurrence: experience at a single institution. *Hepatogastroenterology* 2012;59(115):858-62 Online First.
238. Teng F, Han QC, Ding GS, et al. Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. *Sci Rep* 2015;5:11733 Online First.
239. Tu Z, Xiang P, Xu X, et al. DCD liver transplant infection: Experience from a single centre in China. *Int J Clin Pract* 2016;70:3-10 doi: 10.1111/ijcp.12810published Online First.
240. Vitale A, Cucchetti A, Qiao GL, et al. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit. *J Hepatol* 2014;60(6):1165-71 doi: 10.1016/j.jhep.2014.01.022published Online First.
241. Wan P, Xia Q, Zhang JJ, et al. Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: A single-center experience. *J Cancer Res Clin Oncol* 2014;140(2):341-48 doi: 10.1007/s00432-013-1576-0published Online First.
242. Wan P, Zhang J, Long X, et al. Serum levels of preoperative α -fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. *Eur J Gastroenterol Hepatol* 2014;26(5):553-61 doi: 10.1097/MEG.000000000000070published Online First.
243. Wan Q, Ye Q, Su T, et al. The epidemiology and distribution of pathogens and risk factors for mortality in liver transplant recipients with gram negative bacteremia. *Hepatogastroenterology* 2014;61(134):1730-33 doi: 10.5754/hge14504published Online First.
244. Wan QQ, Ye QF, Ming YZ, et al. The risk factors for mortality in deceased donor liver transplant recipients with bloodstream infections. *Transplant Proc* 2013;45(1):305-07 doi: 10.1016/j.transproceed.2012.06.080published Online First.
245. Wang B, He HK, Cheng B, et al. Effect of low central venous pressure on postoperative pulmonary complications in patients undergoing liver transplantation. *Surg Today* 2013;43(7):777-81 doi: 10.1007/s00595-012-0419-ypublished Online First.

246. Wang C, Wang G, Yi H, et al. Symptom experienced three years after liver transplantation under immunosuppression in adults.[Erratum appears in PLoS One. 2013;8(12). doi:10.1371/annotation/161a6145-d670-408a-a9fc-a1107b57724a]. PLoS ONE [Electronic Resource] 2013;8(11):e80584 Online First.
247. Wang CM, Li X, Song S, et al. Newly designed y-configured single-catheter stenting for the treatment of hilar-type nonanastomotic biliary strictures after orthotopic liver transplantation. *Cardiovasc Intervent Radiol* 2012;35(1):184-89 doi: 10.1007/s00270-011-0214-y published Online First.
248. Wang E, Nie Y, Zhao Q, et al. Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. *J Cardiothorac Surg* 2013;8(1) doi: 10.1186/1749-8090-8-165 published Online First.
249. Wang G, Yang J, Li M, et al. Liver transplant may improve erectile function in patients with benign end-stage liver disease: Single-center Chinese experience. *Exp Clin Transplant* 2013;11(4):332-38 doi: 10.6002/ect.2012.0102 published Online First.
250. Wang GY, Jiang N, Yi HM, et al. Pretransplant elevated plasma fibrinogen level is a novel prognostic predictor for hepatocellular carcinoma recurrence and patient survival following liver transplantation. *Ann Transplant* 2016;21:125-30 doi: 10.12659/AOT.895416 published Online First.
251. Wang GY, Li H, Liu W, et al. Elevated blood eosinophil count is a valuable biomarker for predicting late acute cellular rejection after liver transplantation. *Transplant Proc* 2013;45(3):1198-200 Online First.
252. Wang GY, Yang Y, Li H, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. *PLoS One* 2011;6(9) doi: 10.1371/journal.pone.0025295 published Online First.
253. Wang J, Liu JJ, Liang YY, et al. Could diffusion-weighted imaging detect injured bile ducts of ischemic-type biliary lesions after orthotopic liver transplantation? *American Journal of Roentgenology* 2012;199(4):901-06 doi: 10.2214/AJR.11.8147 published Online First.

254. Wang J, Yang W, Huang Q, et al. Interventional treatment for portal venous occlusion after liver transplantation: Long-term follow-up results. *Medicine (United States)* 2015;94(4) doi: 10.1097/MD.0000000000000356 published Online First.
255. Wang JF, Zhai RY, Wei BJ, et al. Percutaneous intravascular stents for treatment of portal venous stenosis after liver transplantation: midterm results. *Transplant Proc* 2006;38(5):1461-62 doi: 10.1016/j.transproceed.2006.02.113 published Online First.
256. Wang K, Zhu ZJ, Zheng H, et al. Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases. *Hepatology Research* 2012;42(3):280-87 doi: 10.1111/j.1872-034X.2011.00926.x published Online First.
257. Wang L, Li N, Wang MX, et al. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: Findings from a single-center study. *Genetics and Molecular Research* 2015;14(2):3191-99 doi: 10.4238/2015.April.10.31 published Online First.
258. Wang L, Zang Y, Lu S, et al. Efficacy of sirolimus on ischemic-type biliary lesions after liver transplantation. *Int J Clin Exp Med* 2017;10(1):1151-55 Online First.
259. Wang LJ, Liu ZR, Zhang YM, et al. Clinical analysis of liver transplantation for benign liver tumor. *Int J Clin Exp Med* 2016;9(11):22691-95 Online First.
260. Wang P, Li H, Shi B, et al. Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: A single center study. *Oncotarget* 2016;7(23):35071-83 Online First.
261. Wang P, Song W, Li H, et al. Association between donor and recipient smoothed gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population. *Tumor Biology* 2015;36(10):7807-15 doi: 10.1007/s13277-015-3370-x published Online First.
262. Wang P, Wang C, Li H, et al. Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: A single-center experience. *Onco Targets Ther* 2015;8:3775-81 doi: 10.2147/OTT.S93939 published Online First.
263. Wang PL, Wang J, Zhou Y, et al. Expression of programmed death-1 and its ligands in the liver of biliary atresia. *World J Pediatr* 2017:1-7 Online First.

264. Wang S, Li J, Xie A, et al. Dynamic changes in Th1, Th17, and FoxP3+ T cells in patients with acute cellular rejection after cardiac transplantation. *Clin Transplant* 2011;25(2):E177-E86 doi: 10.1111/j.1399-0012.2010.01362.xpublished Online First.
265. Wang SY, Tang HM, Chen GQ, et al. Effect of ursodeoxycholic acid administration after liver transplantation on serum liver tests and biliary complications: A randomized clinical trial. *Digestion* 2012;86(3):208-17 doi: 10.1159/000339711published Online First.
266. Wang W, Ye Y, Wang T, et al. Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil to lymphocyte ratio. *Hepatology Research* 2016;46(9):899-907 doi: 10.1111/hepr.12633published Online First.
267. Wang WL, Jin J, Zheng SS, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. *Liver Transpl* 2006;12(5):775-80 doi: 10.1002/lt.20709published Online First.
268. Wang Y, Liu Y, Han R, et al. Hemostatic variation during perioperative period of orthotopic liver transplantation without venovenous bypass. *Thromb Res* 2008;122(2):161-66 doi: 10.1016/j.thromres.2007.10.002published Online First.
269. Wang Y, Liu Y, Han R, et al. Monitoring of CD95 and CD38 expression in peripheral blood T lymphocytes during active human cytomegalovirus infection after orthotopic liver transplantation. *Journal of Gastroenterology and Hepatology (Australia)* 2010;25(1):138-42 doi: 10.1111/j.1440-1746.2009.05966.xpublished Online First.
270. Wang Y, Liu Y, Han R, et al. Temporal evolution of soluble Fas and Fas ligand in patients with orthotopic liver transplantation. *Cytokine* 2008;41(3):240-43 doi: 10.1016/j.cyto.2007.11.010published Online First.
271. Wang Y, Liu Y, Zhang Y, et al. The role of the CD95, CD38 and TGF β 1 during active human cytomegalovirus infection in liver transplantation. *Cytokine* 2006;35(3-4):193-99 doi: 10.1016/j.cyto.2006.08.001published Online First.
272. Wang Y, Shen Z, Zhu Z, et al. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT. *Hepatitis Monthly* 2011;11(3):195-99 Online First.

273. Wang Y, Zhang M, Liu ZW, et al. The ratio of circulating regulatory T cells (Tregs)/Th17 cells is associated with acute allograft rejection in liver transplantation. *PLoS One* 2014;9(11) doi: 10.1371/journal.pone.0112135 published Online First.
274. Wang YI, Li G, Zhang Y, et al. The expression of von Willebrand factor, soluble thrombomodulin, and soluble p-selectin during orthotopic liver transplantation. *Transplant Proc* 2007;39(1):172-75 doi: 10.1016/j.transproceed.2006.10.027 published Online First.
275. Wang YL, Li G, Wu D, et al. Analysis of alpha-fetoprotein mRNA level on the tumor cell hematogenous spread of patients with hepatocellular carcinoma undergoing orthotopic liver transplantation. *Transplant Proc* 2007;39(1):166-68 doi: 10.1016/j.transproceed.2006.10.008 published Online First.
276. Wang YL, Tang ZQ, Gao W, et al. Influence of Th1, Th2, and Th3 cytokines during the early phase after liver transplantation. *Transplant Proc* 2003;35(8):3024-25 doi: 10.1016/j.transproceed.2003.10.007 published Online First.
277. Wang YL, Zhang YY, Zhou YL, et al. T-helper and T-cytotoxic cell subsets monitoring during active cytomegalovirus infection in liver transplantation. *Transplant Proc* 2004;36(5):1498-99 doi: 10.1016/j.transproceed.2004.05.032 published Online First.
278. Wang Z, Gong W, Shou D, et al. Clonal origin of hepatocellular carcinoma and recurrence after liver transplantation. *Ann Transplant* 2016;21:484-90 Online First.
279. Wang Z, He JJ, Liu XY, et al. The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China. *Immunopharmacol Immunotoxicol* 2015;37(6):508-12 doi: 10.3109/08923973.2015.1096286 published Online First.
280. Wang Z, Liao J, Wu S, et al. Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. *Cancer Gene Ther* 2016;23(6):157-61 doi: 10.1038/cgt.2016.7 published Online First.
281. Wang Z, Shi B, Jin H, et al. Low-dose of tacrolimus favors the induction of functional CD4+CD25+FoxP3+ regulatory T cells in solid-organ transplantation. *Int*

- Immunopharmacol 2009;9(5):564-69 doi: 10.1016/j.intimp.2009.01.029published Online First.
282. Wang Z, Wu S, Chen D, et al. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. *Eur J Clin Pharmacol* 2014;70(8):925-31 doi: 10.1007/s00228-014-1673-2published Online First.
283. Wang ZX, Fu ZR, Ding GS, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. *Transplant Proc* 2004;36(8):2315-7 Online First.
284. Wang ZX, Song SH, Teng F, et al. A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma. *Clin Transplant* 2010;24(6):752-57 doi: 10.1111/j.1399-0012.2009.01172.xpublished Online First.
285. Wang ZX, Yan LN, Wang WT, et al. Impact of pretransplant MELD score on posttransplant outcome in orthotopic liver transplantation for patients with acute-on-chronic hepatitis b liver failure. *Transplant Proc* 2007;39(5):1501-04 doi: 10.1016/j.transproceed.2007.02.070published Online First.
286. Wei Q, Xu X, Wang C, et al. Efficacy and safety of a steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma. *Gut and Liver* 2016;10(4):604-10 doi: 10.5009/gnl15017published Online First.
287. Wei Y, Zhang L, Lin H, et al. Factors related to post-liver transplantation acute renal failure. *Transplant Proc* 2006;38(9):2982-84 doi: 10.1016/j.transproceed.2006.08.156published Online First.
288. Wei YJ, Huang YX, Zhang XL, et al. Apolipoprotein D as a novel marker in human end-stage heart failure: A preliminary study. *Biomarkers* 2008;13(5):535-48 Online First.
289. Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. *Liver Transpl* 2006;12(5):775-80 Online First.
290. Wen O, Li X, Wan Q, et al. The risk factors for mortality and septic shock in liver transplant recipients with ESKAPE bacteremia. *Hepatogastroenterology* 2015;62(138):246-49 doi: 10.5754/hge14092published Online First.
291. Wu B, Wu H, Chen J, et al. Comparative proteomic analysis of human donor tissues during orthotopic liver transplantation: Ischemia versus reperfusion. *Hepatology*

- International 2013;7(1):286-98 doi: 10.1007/s12072-012-9346-7published Online First.
292. Wu CZ, Ni XJ, Zheng SL, et al. A fast SSP-PCR method for genotyping the ATP-binding cassette subfamily B member 1 gene C3435T and G2677T polymorphisms in Chinese transplant recipients. *Tumori* 2009;95(3):338-42 Online First.
293. Wu D, Shen ZY, Zhang YM, et al. Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: A case series. *BMC Cancer* 2015;15(1) Online First.
294. Wu J, Xu X, Liang T, et al. Long-term outcome of combined liver-kidney transplantation: A single-center experience in China. *Hepatogastroenterology* 2008;55(82-83):334-37 Online First.
295. Wu J, Zhu SM, He HL, et al. Plasma propofol concentrations during orthotopic liver transplantation. *Acta Anaesthesiol Scand* 2005;49(6):804-10 doi: 10.1111/j.1399-6576.2005.00671.xpublished Online First.
296. Wu L, Chen L, Zhou L, et al. Association of interleukin 18 gene promoter polymorphisms with HBV recurrence after liver transplantation in Han Chinese population. *Hepatitis Monthly* 2011;11(6):469-74 Online First.
297. Wu L, Hu A, Tam N, et al. Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection. *PLoS One* 2012;7(7) doi: 10.1371/journal.pone.0041820published Online First.
298. Wu L, Tam N, Deng R, et al. Steroid-resistant acute rejection after cadaveric liver transplantation: Experience from one single center. *Clinics and Research in Hepatology and Gastroenterology* 2014;38(5):592-97 doi: 10.1016/j.clinre.2014.04.005published Online First.
299. Wu L, Xu X, Shen J, et al. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. *J Surg Oncol* 2007;96(1):62-68 doi: 10.1002/jso.20774published Online First.
300. Wu L, Zhang J, Guo Z, et al. Diagnosis and treatment of acute appendicitis after orthotopic liver transplant in adults. *Exp Clin Transplant* 2011;9(2):113-17 Online First.

301. Wu L, Zhang J, Guo Z, et al. Hepatic artery thrombosis after orthotopic liver transplant: A review of the same institute 5 years later. *Exp Clin Transplant* 2011;9(3):191-96 Online First.
302. Wu LM, Xie HY, Zhou L, et al. A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation. *Arch Med Res* 2009;40(7):565-70 doi: 10.1016/j.arcmed.2009.07.011published Online First.
303. Wu LM, Yang Z, Zhou L, et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. *PLoS One* 2010;5(12) doi: 10.1371/journal.pone.0014460published Online First.
304. Wu LM, Zhang F, Xie HY, et al. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. *Clin Genet* 2008;73(3):273-78 doi: 10.1111/j.1399-0004.2007.00955.xpublished Online First.
305. Wu LM, Zhang F, Zhou L, et al. Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation. *BMC Cancer* 2010;10 doi: 10.1186/1471-2407-10-399published Online First.
306. Wu Y, Cai B, Tang J, et al. Tacrolimus may induce the production of nucleolar anti-nuclear antibody in liver transplant patients. *J Gastrointestin Liver Dis* 2011;20(3):267-70 Online First.
307. Wu ZW, Lu HF, Wu J, et al. Assessment of the fecal lactobacilli population in patients with hepatitis b virus-related decompensated cirrhosis and hepatitis b cirrhosis treated with liver transplant. *Microb Ecol* 2012;63(4):929-37 doi: 10.1007/s00248-011-9945-1published Online First.
308. Xia D, Yan LN, Li B, et al. Orthotopic liver transplantation for incurable alveolar echinococcosis: Report of five cases from west China. *Transplant Proc* 2005;37(5):2181-84 doi: 10.1016/j.transproceed.2005.03.111published Online First.

309. Xia D, Yan LN, Xu L, et al. Postoperative Severe Pneumonia in Adult Liver Transplant Recipients. *Transplant Proc* 2006;38(9):2974-78 doi: 10.1016/j.transproceed.2006.08.184published Online First.
310. Xia W, Ke Q, Guo H, et al. Expansion of the Milan criteria without any sacrifice: Combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio. *BMC Cancer* 2017;17 (1) Online First.
311. Xia W, Ke Q, Wang Y, et al. Donation after cardiac death liver transplantation: Graft quality evaluation based on pretransplant liver biopsy. *Liver Transpl* 2015;21(6):838-46 doi: 10.1002/lt.24123published Online First.
312. Xia W, Ke Q, Wang Y, et al. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation. *World J Surg Oncol* 2015;13(1) doi: 10.1186/s12957-015-0472-2published Online First.
313. Xia ZW, Jun CY, Hao C, et al. The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients. *Eur J Clin Pharmacol* 2010;66(7):671-79 doi: 10.1007/s00228-010-0833-2published Online First.
314. Xiao H, Tong R, Cheng S, et al. BAG3 and HIF-1 alpha coexpression detected by immunohistochemistry correlated with prognosis in hepatocellular carcinoma after liver transplantation. *BioMed Research International* 2014;2014 Online First.
315. Xiao L, Fu ZR, Ding GS, et al. Liver transplantation for Hepatitis B virus-related hepatocellular carcinoma: one center's experience in China. *Transplant Proc* 2009;41(5):1717-21 doi: 10.1016/j.transproceed.2009.03.058published Online First.
316. Xiao L, Fu ZR, Ding GS, et al. Prediction of survival after liver transplantation for chronic severe hepatitis b based on preoperative prognostic scores: A single center's experience in China. *World J Surg* 2009;33(11):2420-26 doi: 10.1007/s00268-009-0183-3published Online First.
317. Xiao M, Xu X, Zhu H, et al. Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: A single centre study. *Int J Clin Pract* 2015;69(S183):35-42 doi: 10.1111/ijcp.12665published Online First.
318. Xie BX, Zhu YM, Chen C, et al. Outcome of TiNi stent treatments in symptomatic central airway stenoses caused by *Aspergillus fumigatus* infections after lung

- transplantation. *Transplant Proc* 2013;45(6):2366-70 doi: 10.1016/j.transproceed.2013.02.129published Online First.
319. Xie HY, Wang WL, Yao MY, et al. Polymorphisms in cytokine genes and their association with acute rejection and recurrence of Hepatitis B in Chinese liver transplant recipients. *Arch Med Res* 2008;39(4):420-28 doi: 10.1016/j.arcmed.2008.01.003published Online First.
320. Xie M, Rao W, Sun LY, et al. Tacrolimus-related seizure after pediatric liver transplantation - A single-center experience. *Pediatr Transplant* 2014;18(1):58-63 doi: 10.1111/ptr.12198published Online First.
321. Xie M, Rao W, Yang T, et al. Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation. *Liver International* 2015;35(3):897-904 doi: 10.1111/liv.12567published Online First.
322. Xie SB, Zhu JY, Ying Z, et al. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. *Transplantation* 2010;90(7):786-90 doi: 10.1097/TP.0b013e3181f09c89published Online First.
323. Xing T, Huang L, Yu Z, et al. Comparison of Steroid-Free Immunosuppression and Standard Immunosuppression for Liver Transplant Patients with Hepatocellular Carcinoma. *PLoS One* 2013;8(8) doi: 10.1371/journal.pone.0071251published Online First.
324. Xing T, Qiu G, Zhong L, et al. Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: A prospective controlled study. *Pharmazie* 2013;68(10):821-26 doi: 10.1691/ph.2013.3561published Online First.
325. Xing T, Zhong L, Chen D, et al. Experience of combined liver-kidney transplantation for acute-on-chronic liver failure patients with renal dysfunction. *Transplant Proc* 2013;45(6):2307-13 doi: 10.1016/j.transproceed.2013.02.127published Online First.
326. Xing T, Zhong L, Chen D, et al. Experience of combined liver-kidney transplantation for acute-on-chronic liver failure patients with renal dysfunction.[Erratum appears in *Transplant Proc.* 2013 Sep;45(7):2859]. *Transplant Proc* 2013;45(6):2307-13 Online First.

327. Xing T, Zhong L, Lin L, et al. Immunity of fungal infections alleviated graft reject in liver transplantation compared with non-fungus recipients. *Int J Clin Exp Pathol* 2015;8(3):2603-14 Online First.
328. Xing T, Zhong L, Qiu G, et al. Evolution of CD4⁺CD25^{hi} T cell subsets in Aspergillus-infected liver transplantation recipients reduces the incidence of transplantation rejection via upregulating the production of anti-inflammatory cytokines. *Genetics and Molecular Research* 2014;13(3):4932-39 doi: 10.4238/2014.July.4.7published Online First.
329. Xing T, Zhong L, Qiu G, et al. Evolution of CD4⁺CD25^{hi} T cell subsets in Aspergillus-infected liver transplantation recipients reduces the incidence of transplantation rejection via upregulating the production of anti-inflammatory cytokines. *Genetics and Molecular Research* 2014;13(3):4932-39 Online First.
330. Xu G, Li LL, Sun ZT, et al. Effects of dexmedetomidine on postoperative cognitive dysfunction and serum levels of β -amyloid and neuronal microtubule-associated protein in orthotopic liver transplantation patients. *Ann Transplant* 2016;21:508-15 doi: 10.12659/AOT.899340published Online First.
331. Xu H, Li W, Xu Z, et al. Evaluation of the right ventricular ejection fraction during classic orthotopic liver transplantation without venovenous bypass. *Clin Transplant* 2012;26(5):E485-E91 doi: 10.1111/ctr.12010published Online First.
332. Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation. *Hepatology* 2007;45(2):269-76 doi: 10.1002/hep.21465published Online First.
333. Xu L, Li X, Xu M, et al. Perioperative use of ECMO during double lung transplantation. *ASAIO J* 2009;55(3):255-58 doi: 10.1097/MAT.0b013e3181a05795published Online First.
334. Xu L, Xu MQ, Yan LN, et al. Causes of mortality after liver transplantation: A single center experience in mainland China. *Hepatogastroenterology* 2012;59(114):481-84 doi: 10.5754/hge11419published Online First.
335. Xu SL, Zhang YC, Wang GY, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma.

- Clinics and Research in Hepatology and Gastroenterology 2016;40(6):674-81 Online First.
336. Xu X, Guo HJ, Xie HY, et al. ZIP4, a novel determinant of tumor invasion in hepatocellular carcinoma, contributes to tumor recurrence after liver transplantation. *Int J Biol Sci* 2014;10(3):245-56 doi: 10.7150/ijbs.7401published Online First.
337. Xu X, Ke QH, Shao ZX, et al. The value of serum α -fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. *Dig Dis Sci* 2009;54(2):385-88 doi: 10.1007/s10620-008-0349-0published Online First.
338. Xu X, Ling Q, Gao F, et al. Hepatoprotective effects of marine and kuhuang in liver transplant recipients. *Am J Chin Med* 2009;37(1):27-34 Online First.
339. Xu X, Ling Q, Wang J, et al. Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population. *Int J Cancer* 2016;138(3):620-29 Online First.
340. Xu X, Ling Q, Wu J, et al. A novel prognostic model based on serum levels of total bilirubin and creatinine early after liver transplantation. *Liver International* 2007;27(6):816-24 doi: 10.1111/j.1478-3231.2007.01494.xpublished Online First.
341. Xu X, Ling Q, Zhang M, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. *Transplantation* 2009;87(10):1514-19 doi: 10.1097/TP.0b013e3181a4430bpublished Online First.
342. Xu X, Liu X, Ling Q, et al. Artificial liver support system combined with liver transplantation in the treatment of patients with acute-on-chronic liver failure. *PLoS One* 2013;8(3) doi: 10.1371/journal.pone.0058738published Online First.
343. Xu X, Qu K, Wan Y, et al. Tumor existence and tumor size as prognostic factors in hepatitis B virus-related cirrhosis patients who underwent liver transplantation. *Transplant Proc* 2014;46(5):1389-92 doi: 10.1016/j.transproceed.2014.01.011published Online First.
344. Xu X, Tu Z, Wang B, et al. A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. *Liver International* 2011;31(10):1477-84 doi: 10.1111/j.1478-3231.2011.02500.xpublished Online First.

345. Xu ZD, Xu HT, Li WW, et al. Influence of preoperative diastolic dysfunction on hemodynamics and outcomes of patients undergoing orthotopic liver transplantation. *Int J Clin Exp Med* 2013;6(5):351-57 Online First.
346. Xue F, Higgs BW, Huang J, et al. HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. *J Transl Med* 2015;13(1) doi: 10.1186/s12967-015-0743-2published Online First.
347. Xue F, Zhang J, Han L, et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. *Transplantation* 2010;89(5):620-26 doi: 10.1097/TP.0b013e3181c690fapublished Online First.
348. Xue J, Wang L, Chen CM, et al. Acute kidney injury influences mortality in lung transplantation. *Ren Fail* 2014;36(4):541-45 doi: 10.3109/0886022X.2013.876350published Online First.
349. Xue M, Lv C, Chen X, et al. Donor liver steatosis: A risk factor for early new-onset diabetes after liver transplantation. *Journal of Diabetes Investigation* 2017;8(2):181-87 doi: 10.1111/jdi.12560published Online First.
350. Xue M, Lv C, Chen X, et al. Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study. *Journal of Diabetes* 2015 Online First.
351. Yambe T, Meng X, Hou X, et al. Cardio-ankle vascular index (CAVI) for the monitoring of the atherosclerosis after heart transplantation. *Biomed Pharmacother* 2005;59(SUPPL. 1):S177-S79 doi: 10.1016/S0753-3322(05)80028-9published Online First.
352. Yan L, Li B, Wen T, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. *Am J Transplant* 2010;10(8):1861-69 Online First.
353. Yan S, Tu Z, Lu W, et al. Clinical utility of an automated pupillometer for assessing and monitoring recipients of liver transplantation. *Liver Transpl* 2009;15(12):1718-27 doi: 10.1002/lt.21924published Online First.
354. Yang CH, He XS, Chen J, et al. Fungal infection in patients after liver transplantation in years 2003 to 2012. *Ann Transplant* 2012;17(4):59-63 doi: 10.12659/AOT.883695published Online First.

355. Yang J, Zhu L, Zhang Y, et al. PPK analysis of tacrolimus early after Chinese pediatric and adult liver transplantation with different CYP3A5 genotypes. *Latin American Journal of Pharmacy* 2017;36(2):238-46 Online First.
356. Yang JW, Liao SS, Zhu LQ, et al. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. *Int J Clin Pharmacol Ther* 2015;53(1):75-83 doi: 10.5414/CP202189published Online First.
357. Yang X, Lu Q, Tang T, et al. Prediction of the prognosis after liver transplantation in severe hepatitis B-induced liver failure and clinical decision for liver transplantation. *J Surg Res* 2013;183(2):846-51 doi: 10.1016/j.jss.2013.01.034published Online First.
358. Yang YJ, Chen DZ, Li LX, et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. *Transplant Proc* 2008;40(5):1541-44 doi: 10.1016/j.transproceed.2008.01.081published Online First.
359. Yang YL, Shi LJ, Lin MJ, et al. Clinical analysis and significance of cholangiography for biliary cast/stone after orthotopic liver transplantation. *Journal of Nanoscience and Nanotechnology* 2013;13(1):171-77 doi: 10.1166/jnn.2013.6790published Online First.
360. Yang Z, Zhou L, Wu LM, et al. Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. *Clin Chem Lab Med* 2010;48(12):1785-91 doi: 10.1515/CCLM.2010.353published Online First.
361. Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. *Ann Surg Oncol* 2011;18(5):1243-50 doi: 10.1245/s10434-011-1581-ypublished Online First.
362. Yao J, Feng XW, Yu XB, et al. Recipient IL-6-572c/G genotype is associated with reduced incidence of acute rejection following liver transplantation. *J Int Med Res* 2013;41(2):356-64 doi: 10.1177/0300060513477264published Online First.
363. Ye D, Li H, Wang Y, et al. Circulating Fibroblast Growth Factor 21 Is A Sensitive Biomarker for Severe Ischemia/reperfusion Injury in Patients with Liver Transplantation. *Sci Rep* 2016;6:19776 Online First.

364. Yi H, An Y, Lv H, et al. The association of lipopolysaccharide and inflammatory factors with hepatopulmonary syndrome and their changes after orthotopic liver transplantation. *J Thorac Dis* 2014;6(10):1469-75 doi: 10.3978/j.issn.2072-1439.2014.10.05published Online First.
365. Yu D, Liu J, Chen J, et al. GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis. *BMC Cancer* 2014;14 (1) Online First.
366. Yu S, Gao F, Yu J, et al. De novo cancers following liver transplantation: A single center experience in China. *PLoS One* 2014;9 (1) Online First.
367. Yu S, He X, Yang L, et al. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. *Exp Clin Transplant* 2008;6(2):113-17 Online First.
368. Yu S, Wu L, Jin J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. *Transplantation* 2006;81(1):46-51 doi: 10.1097/01.tp.0000188118.34633.bfpublished Online First.
369. Yu S, Yu J, Zhang W, et al. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation. *J Hepatol* 2014;61(4):809-15 Online First.
370. Yu X, Liu Z, Wang Y, et al. Characteristics of gammadelta1 and gammadelta 2 T cell subsets in acute liver allograft rejection. *Transpl Immunol* 2013;29(1-4):118-22 Online First.
371. Yu X, Wei B, Dai Y, et al. Genetic polymorphism of Interferon Regulatory Factor 5 (IRF5) correlates with allograft acute rejection of liver transplantation. *PLoS One* 2014;9(4) doi: 10.1371/journal.pone.0094426published Online First.
372. Yu X, Xie H, Wei B, et al. Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. *PLoS One* 2011;6(11) doi: 10.1371/journal.pone.0025933published Online First.
373. Yu Z, Sun Z, Yu S, et al. Safety limitations of fatty liver transplantation can be extended to 40%: Experience of a single centre in China. *Liver International* 2016 Online First.

374. Yuan D, Wei YG, Lin HM, et al. Risk factors of biliary complications following liver transplantation: Retrospective analysis of a single centre. *Postgrad Med J* 2009;85(1001):119-23 doi: 10.1136/pgmj.2008.075176published Online First.
375. Yuan X, Chen C, Zhou J, et al. Organ donation and transplantation from donors with systemic infection: a single-center experience. *Transplant Proc* 2016;48(7):2454-57 Online First.
376. Yuefeng M, Weili F, Wenxiang T, et al. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation. *Clin Transplant* 2011;25(4):517-22 Online First.
377. Zeng Z, Jiang Z, Wang CS, et al. Preoperative evaluation improves the outcome in heart transplant recipients with pulmonary hypertension-retrospective analysis of 106 cases. *Transplant Proc* 2010;42(9):3708-10 doi: 10.1016/j.transproceed.2010.08.067published Online First.
378. Zhai H, Liang P, Yu XL, et al. Microwave ablation in treating intrahepatic recurrence of hepatocellular carcinoma after liver transplantation: An analysis of 11 cases. *Int J Hyperthermia* 2015;31(8):863-68 doi: 10.3109/02656736.2015.1091953published Online First.
379. Zhang A, Zhang M, Shen Y, et al. Hepatitis B virus reactivation is a risk factor for development of post-transplant lymphoproliferative disease after liver transplantation. *Clin Transplant* 2009;23(5):756-60 doi: 10.1111/j.1399-0012.2009.01049.xpublished Online First.
380. Zhang C, Rao J, Tu Z, et al. Surgical resection of resectable thoracic metastatic hepatocellular carcinoma after liver transplantation. *J Thorac Cardiovasc Surg* 2009;138(1):240-41 doi: 10.1016/j.jtcvs.2008.05.014published Online First.
381. Zhang D, Jiao Z, Han J, et al. Clinicopathological features of hepatitis B virus recurrence after liver transplantation: Eleven-year experience. *Int J Clin Exp Pathol* 2014;7(7):4057-66 Online First.
382. Zhang F, Wu LM, Zhou L, et al. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma

- treated with transplantation. *Ann Surg Oncol* 2008;15(12):3494-502 doi: 10.1245/s10434-008-0146-1published Online First.
383. Zhang FJ, Li CX, Liang Z, et al. Short- to mid-term evaluation of CT-guided 125I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma. *Cancer Biology and Therapy* 2009;8(7):585-90 Online First.
384. Zhang G, Cheng Y, Shen W, et al. The short-term effect of liver transplantation on the low-frequency fluctuation of brain activity in cirrhotic patients with and without overt hepatic encephalopathy. *Brain Imaging and Behavior* 2016:1-13 Online First.
385. Zhang H, Chen L, Gu G, et al. Clinical observation and nursing care on the prevention of abdominal organ cluster transplantation rejection. *J Clin Nurs* 2013;22(11-12):1599-603 doi: 10.1111/jocn.12079published Online First.
386. Zhang H, Shi Y, Wu H, et al. Change of hepatic arterial systolic/diastolic ratio predicts ischemic type biliary lesion after orthotopic liver transplantation. *Clin Imaging* 2016;40(3):419-24 Online First.
387. Zhang HM, Jiang WT, Pan C, et al. Milan criteria, University of California, San Francisco, criteria, and model for end-stage liver disease score as predictors of salvage liver transplantation. *Transplant Proc* 2015;47(2):438-44 doi: 10.1016/j.transproceed.2014.10.046published Online First.
388. Zhang HM, Li SP, Yu Y, et al. Bi-directional roles of IRF-1 on autophagy diminish its prognostic value as compared with Ki67 in liver transplantation for hepatocellular carcinoma. *Oncotarget* 2016;7(25):37979-92 doi: 10.18632/oncotarget.9365published Online First.
389. Zhang LJ, Yang GF, Jiang B, et al. Cavernous transformation of portal vein: 16-Slice CT portography and correlation with surgical procedure of orthotopic liver transplantation. *Abdom Imaging* 2008;33(5):529-35 doi: 10.1007/s00261-007-9343-9published Online First.
390. Zhang M, Yin F, Chen B, et al. Mortality risk after liver transplantation in hepatocellular carcinoma recipients: A nonlinear predictive model. *Surgery (United States)* 2012;151(6):889-97 doi: 10.1016/j.surg.2011.12.034published Online First.

391. Zhang M, Yin F, Chen B, et al. Pretransplant prediction of posttransplant survival for liver recipients with benign end-stage liver diseases: A nonlinear model. *PLoS One* 2012;7 (3) Online First.
392. Zhang M, Zhong X, Zhang W, et al. Human parvovirus B19 infection induced pure red cell aplasia in liver transplant recipients. *Int J Clin Pract* 2015;69(S183):29-34 doi: 10.1111/ijcp.12664published Online First.
393. Zhang ML, Xu J, Zhang W, et al. Microbial epidemiology and risk factors of infections in recipients after DCD liver transplantation. *Int J Clin Pract* 2016;70:17-21 doi: 10.1111/ijcp.12812published Online First.
394. Zhang P, Guo Z, Zhong K, et al. Evaluation of Immune Profiles and MicroRNA Expression Profiles in Peripheral Blood Mononuclear Cells of Long-Term Stable Liver Transplant Recipients and Recipients with Acute Rejection Episodes. *Transplant Proc* 2015;47(10):2907-15 doi: 10.1016/j.transproceed.2015.10.048published Online First.
395. Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: A preliminary open-label study. *Invest New Drugs* 2011;29(6):1360-69 doi: 10.1007/s10637-011-9726-1published Online First.
396. Zhang Q, Chen X, Zang Y, et al. The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis b virus infection and cirrhosis. *PLoS One* 2012;7(12) doi: 10.1371/journal.pone.0050919published Online First.
397. Zhang Q, Chen X, Zhou J, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. *Cancer Biol Ther* 2006;5(7):808-14 Online First.
398. Zhang Q, Shang L, Zang Y, et al. α -Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation. *Eur J Gastroenterol Hepatol* 2014;26(5):544-52 doi: 10.1097/MEG.000000000000029published Online First.
399. Zhang W, Zhong H, Zhuang L, et al. Peripheral blood CD4+ cell ATP activity measurement to predict HCC recurrence post-DCD liver transplant. *Int J Clin Pract* 2016;70:11-16 doi: 10.1111/ijcp.12811published Online First.

400. Zhang X, Fan J, Yang MF, et al. Monitoring of human cytomegalovirus infection in bone marrow and liver transplant recipients by antigenaemia assay and enzyme-linked immunosorbent assay. *J Int Med Res* 2009;37(1):31-36 Online First.
401. Zhang X, Wang Z, Fan J, et al. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. *Eur J Clin Pharmacol* 2011;67(8):803-13 doi: 10.1007/s00228-011-0993-8published Online First.
402. Zhang X, Xu J, Fan J, et al. Influence of IL-18 and IL-10 Polymorphisms on tacrolimus elimination in Chinese lung transplant patients. *Dis Markers* 2017;2017 doi: 10.1155/2017/7834035published Online First.
403. Zhang XD, Cheng Y, Poon CS, et al. Long-and short-range functional connectivity density alteration in non-alcoholic cirrhotic patients one month after liver transplantation: A resting-state fMRI study. *Brain Res* 2015;1620:177-87 doi: 10.1016/j.brainres.2015.04.046published Online First.
404. Zhang XF, Lv Y, Xue WJ, et al. Mycobacterium tuberculosis Infection in Solid Organ Transplant Recipients: Experience From a Single Center in China. *Transplant Proc* 2008;40(5):1382-85 doi: 10.1016/j.transproceed.2008.01.075published Online First.
405. Zhang XQ, Wang ZW, Fan JW, et al. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. *Ther Drug Monit* 2012;34(2):126-33 doi: 10.1097/FTD.0b013e31824a67ebpublished Online First.
406. Zhang XX, Bian RJ, Wang J, et al. Relationship between cytokine gene polymorphisms and acute rejection following liver transplantation. *Genetics and Molecular Research* 2016;15 (2) 15027599) Online First.
407. Zhang Y, Wang YL, Liu YW, et al. Change of peripheral blood mononuclear cells IFN- γ , IL-10, and TGF- β 1 mRNA expression levels with active human cytomegalovirus infection in orthotopic liver transplantation. *Transplant Proc* 2009;41(5):1767-69 doi: 10.1016/j.transproceed.2009.03.064published Online First.
408. Zhang Y, Yan L, Wen T, et al. Prophylaxis against hepatitis B virus recurrence after liver transplantation for hepatitis B virus-related end-stage liver diseases with severe

- hypersplenism and splenomegaly: Role of splenectomy. *J Surg Res* 2012;178(1):478-86 doi: 10.1016/j.jss.2012.02.047published Online First.
409. Zhang YC, Liu W, Fu BS, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation. *Cytotherapy* 2017;19(2):194-99 Online First.
410. Zhang YC, Qu EZ, Ren J, et al. New diagnosis and therapy model for ischemic-type biliary lesions following liver transplantation-a retrospective cohort study. *PLoS One* 2014;9(9) doi: 10.1371/journal.pone.0105795published Online First.
411. Zheng RQ, Mao R, Ren J, et al. Contrast-enhanced ultrasound for the evaluation of hepatic artery stenosis after liver transplantation: Potential role in changing the clinical algorithm. *Liver Transpl* 2010;16(6):729-35 doi: 10.1002/lt.22054published Online First.
412. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. *Liver Transpl* 2006;12(2):253-58 doi: 10.1002/lt.20701published Online First.
413. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. *Transplantation* 2008;85(12):1726-32 doi: 10.1097/TP.0b013e31816b67e4published Online First.
414. Zheng Z, Gao S, Yang Z, et al. Single nucleotide polymorphisms in the metastasis associated in colon cancer-1 gene predict the recurrence of hepatocellular carcinoma after transplantation. *Int J Med Sci* 2014;11(2):142-50 doi: 10.7150/ijms.7142published Online First.
415. Zheng Z, Lin B, Zhang J, et al. Absolute lymphocyte count recovery at 1 month after transplantation predicts favorable outcomes of patients with hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology (Australia)* 2015;30(4):706-11 doi: 10.1111/jgh.12782published Online First.
416. Zhenglu W, Hui L, Shuying Z, et al. A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. *Transplant Proc* 2007;39(10):3287-91 doi: 10.1016/j.transproceed.2007.08.096published Online First.

417. Zhong L, Li H, Li Z, et al. C7 genotype of the donor may predict early bacterial infection after liver transplantation. *Sci Rep* 2016;6:24121 Online First.
418. Zhong L, Men TY, Li H, et al. Multidrug-resistant gram-negative bacterial infections after liver transplantation - Spectrum and risk factors. *J Infect* 2012;64(3):299-310 doi: 10.1016/j.jinf.2011.12.005published Online First.
419. Zhong X, Zhang W, Xu J, et al. Human parvovirus B19 infection induced pure red cell aplasia in liver transplant recipients. *Int J Clin Pract* 2015;69(S183):29-34 Online First.
420. Zhong ZQ, Luo AJ, Wan QQ, et al. Pseudomonas aeruginosa infection among liver transplant recipients: a clinical analysis of 15 cases. *Transplant Proc* 2016;48(6):2130-34 Online First.
421. Zhongyang S, Yihe L, Lixin Y, et al. An experience from China of perioperative care in 1510 liver transplant recipients. *Int Anesthesiol Clin* 2006;44(4):121-26 doi: 10.1097/01.aia.0000210820.31029.92published Online First.
422. Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. *J Vasc Interv Radiol* 2010;21(3):333-38 doi: 10.1016/j.jvir.2009.11.006published Online First.
423. Zhou J, Fan J, Wang JH, et al. Continuous transcatheter arterial thrombolysis for early hepatic artery thrombosis after liver transplantation. *Transplant Proc* 2005;37(10):4426-29 doi: 10.1016/j.transproceed.2005.10.113published Online First.
424. Zhou J, Huang H, Liu S, et al. Staphylococcus Aureus bacteremias following liver transplantation: A clinical analysis of 20 cases. *Ther Clin Risk Manag* 2015;11:933-37 doi: 10.2147/TCRM.S84579published Online First.
425. Zhou J, Ju W, Yuan X, et al. ABO-incompatible liver transplantation for severe hepatitis B patients. *Transpl Int* 2015;28(7):793-99 doi: 10.1111/tri.12531published Online First.
426. Zhou J, Wang Z, Qiu SJ, et al. Surgical treatment for early hepatocellular carcinoma: Comparison of resection and liver transplantation. *J Cancer Res Clin Oncol* 2010;136(9):1453-60 doi: 10.1007/s00432-010-0802-2published Online First.

427. Zhou J, Wang Z, Wu ZQ, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the milan criteria. *Transplant Proc* 2008;40(10):3548-53 doi: 10.1016/j.transproceed.2008.03.165published Online First.
428. Zhou L, Fan J, Zheng SS, et al. Prevalence of human cytomegalovirus UL97 D605E mutation in transplant recipients in China. *Transplant Proc* 2006;38(9):2926-28 doi: 10.1016/j.transproceed.2006.08.161published Online First.
429. Zhou L, Wei B, Xing C, et al. Polymorphism in 3'-untranslated region of toll-like receptor 4 gene is associated with protection from hepatitis B virus recurrence after liver transplantation. *Transpl Infect Dis* 2011;13(3):250-58 doi: 10.1111/j.1399-3062.2010.00574.xpublished Online First.
430. Zhou L, Zhou W, Wu L, et al. The association of frequent allelic loss on 17p13.1 with early metastatic recurrence of hepatocellular carcinoma after liver transplantation. *J Surg Oncol* 2010;102(7):802-08 doi: 10.1002/jso.21743published Online First.
431. Zhou Q, Wang Y, Zhou X, et al. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. *Asian Pac J Cancer Prev* 2011;12(11):2847-50 Online First.
432. Zhou ZB, Shao XX, Yang XY, et al. Influence of Hydroxyethyl starch on renal function after orthotopic liver transplantation. *Transplant Proc* 2015;47(6):1616-19 doi: 10.1016/j.transproceed.2015.04.095published Online First.
433. Zhu B, Chen Y, Xie Y, et al. Kaposi's sarcoma-associated herpesvirus (KSHV) infection: Endemic strains and cladograms from immunodeficient patients in China. *J Clin Virol* 2008;42(1):7-12 Online First.
434. Zhu L, Wang H, Rao W, et al. A limited sampling strategy for tacrolimus in liver transplant patients. *Int J Clin Pharmacol Ther* 2013;51(6):509-12 doi: 10.5414/CP201876published Online First.
435. Zhu L, Yang J, Jing Y, et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. *Xenobiotica* 2015;45(9):840-46 Online First.

436. Zhu M, Li Y, Xia Q, et al. Strong impact of acute kidney injury on survival after liver transplantation. *Transplant Proc* 2010;42(9):3634-38 doi: 10.1016/j.transproceed.2010.08.059published Online First.
437. Zhu Q, Zhou L, Yang Z, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. *Med Oncol* 2012;29(2):985-93 doi: 10.1007/s12032-011-9912-1published Online First.
438. Zhu X, Wu Y, Qiu Y, et al. Effects of ω -3 fish oil lipid emulsion combined with parenteral nutrition on patients undergoing liver transplantation. *Journal of Parenteral and Enteral Nutrition* 2013;37(1):68-74 doi: 10.1177/0148607112440120published Online First.
439. Zhu XD, Shen ZY, Chen XG, et al. Pathotyping and clinical manifestations of biliary cast syndrome in patients after an orthotopic liver transplant. *Exp Clin Transplant* 2013;11(2):142-49 doi: 10.6002/ect.2012.0035published Online First.
440. Zhu XS, Gao YH, Wang SS, et al. Contrast-enhanced ultrasound diagnosis of splenic artery steal syndrome after orthotopic liver transplantation. *Liver Transpl* 2012;18(8):966-71 doi: 10.1002/lt.23453published Online First.
441. Zhu XS, Wang SS, Cheng Q, et al. Using ultrasonography to monitor liver blood flow for liver transplant from donors supported on extracorporeal membrane oxygenation. *Liver Transpl* 2016;22(2):188-91 doi: 10.1002/lt.24318published Online First.
442. Zhu ZJ, Shen ZY, Gao W, et al. Feasibility of using a liver infected with *Clonorchis sinensis* for liver transplantation: Fourteen cases. *Liver Transpl* 2010;16(12):1440-42 doi: 10.1002/lt.22147published Online First.
443. Zicheng Y, Weixia Z, Hao C, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant. *Ther Drug Monit* 2007;29(2):207-14 doi: 10.1097/FTD.0b013e318040ce0bpublished Online First.
444. Zou SJ, Chen D, Li YZ, et al. Monitoring hepatocyte dysfunction and biliary complication after liver transplantation using quantitative hepatobiliary scintigraphy. *Medicine (United States)* 2015;94(45):e2009 doi: 10.1097/MD.0000000000002009published Online First.

445. Zou Y, Yang X, Jiang X, et al. High levels of soluble Major Histocompatibility Complex class I related chain A (MICA) are associated with biliary cast syndrome after liver transplantation. *Transpl Immunol* 2009;21(4):210-14 doi: 10.1016/j.trim.2009.06.003 published Online First.